Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3D059
- Development stage
- Preclinical
- Lead developer
- 3D Medicines
- Modality
- Vaccines & Immunotherapeutics
01
Overview
3D059 is a preclinical-stage tumor vaccine developed by 3D Medicines. It is designed to target the Wilms' Tumor 1 (WT1) protein, a zinc-finger transcription factor that is overexpressed in various hematologic malignancies and solid tumors but has limited expression in normal adult tissues. The vaccine aims to stimulate the patient's immune system to generate a specific T-cell response against WT1-expressing cancer cells. 3D059 is being investigated for multiple oncology indications and represents an earlier-stage asset in 3D Medicines' pipeline, distinct from their clinical-stage WT1 vaccine 3D189 (Galinpepimut-S).
02
Targets
WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on 3D059.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3D059.